Intellia Therapeutics, Inc. (NTLA)
12.55
-0.29
(-2.26%)
USD |
NASDAQ |
Aug 24, 16:00
12.55
0.00 (0.00%)
After-Hours: 19:19
Intellia Therapeutics Debt to Equity Ratio : 0.1009 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1009 |
| March 31, 2026 | 0.1296 |
| December 31, 2025 | 0.139 |
| September 30, 2025 | 0.1309 |
| June 30, 2025 | 0.1434 |
| March 31, 2025 | 0.1529 |
| December 31, 2024 | 0.2411 |
| September 30, 2024 | 0.1056 |
| June 30, 2024 | 0.1095 |
| March 31, 2024 | 0.107 |
| December 31, 2023 | 0.1098 |
| September 30, 2023 | 0.1141 |
| June 30, 2023 | 0.1107 |
| March 31, 2023 | 0.1059 |
| December 31, 2022 | 0.1058 |
| September 30, 2022 | 0.1184 |
| June 30, 2022 | 0.079 |
| March 31, 2022 | 0.0753 |
| December 31, 2021 | 0.0712 |
| September 30, 2021 | 0.0686 |
| June 30, 2021 | 0.1428 |
| Date | Value |
|---|---|
| March 31, 2021 | 0.1333 |
| December 31, 2020 | 0.0746 |
| September 30, 2020 | 0.0673 |
| June 30, 2020 | 0.0659 |
| March 31, 2020 | 0.0983 |
| December 31, 2019 | 0.0681 |
| September 30, 2019 | 0.0713 |
| June 30, 2019 | 0.071 |
| March 31, 2019 | 0.0738 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Beam Therapeutics, Inc. | 0.2317 |
| Twist Bioscience Corp. | 0.21 |
| Tenaya Therapeutics, Inc. | 0.0569 |
| Moderna, Inc. | 0.1904 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 857.16M |
| Total Liabilities (Quarterly) | 129.46M |
| Shareholders Equity (Quarterly) | 727.71M |
| Current Ratio | 6.648 |
| Net Debt Paydown Yield | 0.39% |